ROS, stress-activated kinases and stress signaling in cancer

Moran Benhar, David Engelberg & Alexander Levitzki+

Department of Biological Chemistry, The Alexander Silberman Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem 91904, Israel

Received November 16, 2001; revised February 28, 2002; accepted March 1, 2002

Anticancer therapy is frequently efficient in early stages of the disease, whereas advanced tumors are usually resistant to the same treatments. The molecular basis for this change is not entirely understood. Many anticancer agents are DNA- or cytoskeleton-damaging drugs that show some specificity towards dividing cells. However, recent studies show that these agents also activate stress-signaling cascades that may play a role in eliciting the observed therapeutic effects. We discuss recent findings that suggest that induction of stress signaling in oncogenically transformed cells is integrated into apoptotic pathways. Reactive oxygen species (ROS) and stress-activated protein kinases (SAPKs), which are potentiated in recently transformed cells, emerge as key effectors of cell death. In advanced tumors, however, these agents are down-regulated and, consequently, death signaling is suppressed. Such changes in ROS and SAPK activity levels during the course of tumor development may underlie the changes in responsiveness to anticancer therapy.

Introduction

Mortality from cancer has not changed significantly since the ‘War on cancer’ was declared by an act of the US Congress 30 years ago. Billions of dollars have been invested in cancer research, but progress toward a cure has been painfully slow. It is well known that, in the early stages of the disease, cancer cells are more vulnerable to chemotherapy and radiotherapy than normal cells, but, as the disease progresses, they lose their preferential sensitivity to the same treatments. Understanding this shift in cellular behavior is essential if we wish to eliminate metastatic cancer cells by dismantling the shield that they acquire.

When cytotoxic drugs were originally generated, they were believed to target the cancer cell quite selectively, since they mainly damage rapidly dividing cells. Today, we understand that this simplistic view is inaccurate. We now recognize that cytotoxic agents, as well as ionizing radiation, are often effective treatments not only because they cause cellular injury directly, but also because they induce stress responses as a consequence of damage to the DNA or the cytoskeleton. In many cases, induction of the cellular stress response results in apoptotic cell death, a feature not appreciated until a few years ago. This linkage between cytotoxic therapy, stress signaling and apoptosis may hold the key to a deeper understanding of the cancer cell and may unravel its Achilles’ heel.

Cancer cells are sensitized to stress

An emerging view is that, upon oncogenic transformation, cells activate a stress response primarily as a protective measure. Indeed, oncogenes are well known for their ability to drive cells to senescence or cell death (Evan and Vousden, 2001). In order to survive, transformed cells need to suppress these stress signals. However, this suppression is not complete, since, in the early stages of oncogenesis, the surviving transformed cells may still be sensitized to stress from other sources, including the DNA damage induced by anticancer agents (Benhar et al., 2001; Figure 1). Cells with these properties are referred to as being in the ‘potentiated state’. The cells that ultimately survive to become tumors are further selected to survive adverse environmental conditions such as hypoxia, lack of growth and survival factors or reduced substratum adhesion. Thus, the potentiated state is gradually lost or shielded by anti-apoptotic robustness (Brown and Wouters, 1999). Understanding the molecular events that underlie these phenomena is a great challenge in cancer research. Here, we discuss recent discoveries related to stress signaling in cancer. Specifically, findings on the functions of reactive oxygen species (ROS) and stress-activated kinases are discussed in the framework of the cellular stress response during the evolution of the malignant state (Figure 1). It should be noted

*Corresponding author. Tel: +972 2 6585404; Fax: +972 2 6512958; E-mail: levitzki@vms.huji.ac.il
ROS, stress-activated kinases and stress signaling in cancer

Mitogen-activated protein kinases (MAPKs) are components of kinase cascades that connect extracellular stimuli to specific transcription factors, thereby converting these signals into cellular responses. In mammalian systems, there are three groups of MAPKs: ERKs (extracellular signal-regulated kinases), JNKs (c-Jun N-terminal kinases) and p38 MAPKs. Extensive research has documented the pivotal roles of the ERK subgroup in proliferative responses and of the stress-activated protein kinases (SAPKs) JNK and p38 subgroups in stress responses and in programmed cell death (Lewis et al., 1998; Davis, 2000; Kyriakis and Avruch, 2001).

SAPKs have been studied primarily in the context of stress responses and apoptosis. However, accumulating genetic and biochemical data suggest that SAPKs, and especially the JNK pathway, contribute to proliferative responses in a non-stress setting. For example, JNK1−/− mouse embryonic fibroblasts (MEFs), as well as JNK1−/−JNK2−/− MEFs, proliferate more slowly than do wild-type MEFs and reach a lower saturation density, establishing that JNK is required for normal MEF proliferation (Tournier et al., 2000). JNK and p38 also have been shown to cooperate with ERK in pp60(v-src)-induced cyclin D1 expression in breast cancer cells (Lee et al., 1999). A role for JNK in cancer development is supported by recent studies. In one, it was shown that skin tumorigenesis is suppressed in JNK2-deficient mice (Chen et al., 2001a), and, in another, expression of an inactive variant of the JNK substrate c-Jun (JunAA, lacking JNK phosphorylation sites) in immortalized fibroblasts expressing v-src and v-flt was shown to reduce tumorigenicity in nude mice (Behrens et al., 2000). These and other data (Table I) suggest that signaling through the JNK pathway mediates oncogenic signals and supports cell proliferation in the absence of stress.

Under stress, on the other hand, activation of SAPKs appears to be important in promoting apoptosis in many cell types, including tumor cells and transformed cells in culture. A detailed
In their pro-apoptotic actions (Fuchs et al., 1999), which augments the p53 response, may also play a role in regulating the behavior of the transformed cell. In one study, increased ROS levels stimulated MAPK activity in a mouse keratinocyte cell line that had progressed to malignancy (Gupta et al., 1999). Overexpression of manganese superoxide dismutase (MnSOD), in another case, reduced oxidative stress and thereby facilitating JNK activation (Adler et al., 2000b), and additional, yet unknown, mechanisms linking ROS and SAPKs undoubtedly exist. For instance, scaffold proteins have been gaining interest as a mechanism for SAPK regulation (Davis, 1999; Shiah et al., 1999). Recent studies offer some mechanisms linking ROS and SAPKs. ASK1, an upstream regulator of SAPKs, is inhibited in non-stressed cells through its association with thioredoxin (Raitano et al., 2000). A similar redox ‘switch’ has been documented for JNK, with ROS triggering the detachment of JNK associated glutathione-S-transferase-π (GSTp) and thereby facilitating JNK activation (Adler et al., 1999). ROS-dependent activation of JNK may also involve downregulation of a JNK phosphatase (Chen et al., 2001a) and additional, as yet unknown, mechanisms linking ROS and SAPKs undoubtedly exist. For instance, scaffold proteins have been gaining interest as a mechanism for SAPK regulation (Davis, 1999; Shiah et al., 1999). Recent studies offer some mechanisms linking ROS and SAPKs. ASK1, an upstream regulator of SAPKs, is inhibited in non-stressed cells through its association with thioredoxin (Saitoh et al., 1998). Increased ROS levels lead to the dissociation of this complex and thereby enable the activation of ASK1 and downstream SAPKs (Liu et al., 2000). A similar redox ‘switch’ has been documented for JNK, with ROS triggering the detachment of JNK associated glutathione-S-transferase-π (GSTp) and thereby facilitating JNK activation (Adler et al., 1999). ROS-dependent activation of JNK may also involve downregulation of a JNK phosphatase (Chen et al., 2001b), and additional, as yet unknown, mechanisms linking ROS and SAPKs undoubtedly exist. For instance, scaffold proteins have been gaining interest as a mechanism for SAPK regulation (Davis, 2000), and the possibility that ROS-induced SAPK activation involves modulation of protein scaffolds merits investigation. All this evidence indicates that ROS do not act within the cell solely to induce random damage, as thought previously. Rather, ROS levels fluctuate in response to intracellular as well as extracellular signals and, in turn, stimulate specific signaling cascades (such as those involving MAPKs) that regulate cell growth and cell death.

ROS and stress kinase signaling

Potentiation of SAPKs in transformed murine cells was shown to be independent of the particular overexpressed proto-oncogene but dependent on ROS, whose production is elevated in these cells (Benhar et al., 2001). These observations were extended to the situation in human cells, where higher ROS and SAPK activity were measured in tumor cells that were sensitive to anticancer agents than in those that were drug-resistant (Benhar et al., 2001). Other data further implicate ROS-dependent MAPK activation in regulating the behavior of the transformed cell. In one study, increased ROS levels stimulated MAPK activity in a mouse keratinocyte cell line that had progressed to malignancy (Gupta et al., 1999). Overexpression of manganese superoxide dismutase (MnSOD), in another case, reduced oxidative stress, inhibited the JNK/AP-1 pathway and suppressed tumor formation in a multistage skin carcinogenesis model (Zhao et al., 2001). Redox regulation also appears to be important in SAPK activation under stress (Adler et al., 1999; Davis et al., 2001).

For example, it has been demonstrated that ROS function as intermediates in SAPK activation in response to stress agents such as ceramide and anticancer drugs (Mansat-de Mas et al., 1999; Shiah et al., 1999).

Recent studies offer some mechanisms linking ROS and SAPKs. ASK1, an upstream regulator of SAPKs, is inhibited in non-stressed cells through its association with thioredoxin (Saitoh et al., 1998). Increased ROS levels lead to the dissociation of this complex and thereby enable the activation of ASK1 and downstream SAPKs (Liu et al., 2000). A similar redox ‘switch’ has been documented for JNK, with ROS triggering the detachment of JNK associated glutathione-S-transferase-π (GSTp) and thereby facilitating JNK activation (Adler et al., 1999). ROS-dependent activation of JNK may also involve downregulation of a JNK phosphatase (Chen et al., 2001b), and additional, as yet unknown, mechanisms linking ROS and SAPKs undoubtedly exist. For instance, scaffold proteins have been gaining interest as a mechanism for SAPK regulation (Davis, 2000), and the possibility that ROS-induced SAPK activation involves modulation of protein scaffolds merits investigation. All this evidence indicates that ROS do not act within the cell solely to induce random damage, as thought previously. Rather, ROS levels fluctuate in response to intracellular as well as extracellular signals and, in turn, stimulate specific signaling cascades (such as those involving MAPKs) that regulate cell growth and cell death.

ROS and MAP kinases: complex roles in tumor cell behavior

The diverse, and even opposing, effects of ROS on cell behavior outlined above could be explained by the notion that growth is maximally promoted when cells are protected from excessive toxicity but maintain an oxidant signal sufficient for the induction of growth-competence genes. Thus, under optimal growth conditions, elevated ROS levels confer a growth advantage to tumor cells. However, exposure of these cells to damaging agents induces a prolonged increase in ROS levels resulting in potentiation of apoptosis. Hence, these tumor cells are hypersensitive to stress...
signals. Conversely, in drug-resistant tumors, glutathione or other antioxidant defenses are often upregulated (Shen et al., 1997), shielding cells from apoptosis. As in the case of ROS, the ability of stress kinases to stimulate cell growth or cell death most likely depends on signal intensity and signal duration. This concept has been invoked to explain complex functions of ERK in cell-cycle regulation (Roovers and Assoian, 2000) and in SAPK signaling (Chen et al., 1996). Thus, transient, low-level activity of SAPK promotes cell proliferation, whereas persistent, high-level activity results in cell death.

Based on the studies reviewed above, we propose the following model that explains the sensitized state of tumor cells (Figure 2). In non-transformed cells, ROS levels and SAPK activity are relatively low. The process of oncogenic transformation leads to an elevation in the basal levels of ROS (under non-stress conditions) and to a potentiation of SAPK activity. This intermediate state facilitates mitogenic signaling through the activation of AP-1 or through other mechanisms discussed above. Upon exposure of cells to stress stimuli such as anticancer agents, ROS levels and SAPK activity are elevated. In the transformed cells, where basal stress signaling is the potentiated state, additional stress stimuli result in substantially higher levels of ROS and SAPK activity, which, in turn, augment the apoptotic response of these cells. This model can be extended to the circumstances of the advanced cancer, where the situation is reversed. In other words, following many generations of selection, ROS levels decrease (due to elevated antioxidant activity) and SAPK activity is suppressed, conferring greater stress resistance upon these cells. This notion implies that active SAPKs can suppress cancer progression to advanced stages. Indeed, SEK1 (MKK4), the upstream activator of JNK, has been implicated as a prostate cancer metastasis suppressor gene (Yoshida et al., 1999). Furthermore, the expression of MKP-1, a JNK phosphatase, is elevated in prostate cancer (Magi-Galluzzi et al., 1997), and the hypoxic conditions found in the environment of solid tumors also induce MKP-1 expression, thereby inhibiting JNK activity (Laderoute et al., 1999). These data indicate that the progression of tumor cells towards the metastatic state is characterized by suppression of the JNK pathway.

**Anti-apoptotic signaling and stress: therapeutic implications**

Whereas the potentiated stress state is readily observed in some tumor cells, in other cases it is masked by the activation of anti-apoptotic signaling. If this shield could be removed, the potentiated stress state might be regained, with the cells becoming re-sensitized to death signals. A number of examples imply that this can be achieved. For example, non-small-cell lung carcinoma cells become more resistant to cytotoxic agents such as cisplatin, doxorubicin and etoposide as the level of Her-2/neu expression is elevated, but upon blockade of Her-2/neu signaling the cells become re-sensitized to these agents (Tsai et al., 1996). Similarly, the overexpression of a mutated EGFR in advanced glioma correlates with resistance to cisplatin due to reduced apoptosis, and blocking EGFR signaling in these cells restores their cisplatin sensitivity (Nagane et al., 1998). Blocking Her-2 with Herceptin (Trastuzumab) sensitizes highly drug-resistant breast cancer cells to cytotoxic drugs (Pegram et al., 2000). In fact, the approach of 'chemo-signal therapy,' namely, the combination of chemotherapy with cellular response modifiers, has shown promising results in clinical trials (Pusztai et al., 1999). How these combined therapies modulate ROS and stress kinase pathways at the cellular level has not been determined. Yet, in prostate cancer cells, inhibition of HER-2/neu signaling triggers p38 activation and apoptosis (Murillo et al., 2001).

In summary, both ROS metabolism and MAP kinase signaling are dysregulated in cancer. In this review, we have discussed recent findings illustrating that ROS and SAPKs affect each other and together play an important role in determining the cells' responsiveness to apoptotic signals. The study of stress signaling has proved to be instructive in explaining recent advances in cancer therapy and should facilitate the development of improved anticancer strategies.

**References**


review

M. Benhar, D. Engelberg & A. Levitzki


ROS, stress-activated kinases and stress signaling in cancer


David Engelberg, Moran Benhar & Alexander Levitzki

DOI: 10.1093/embo-reports/kvf094